Lubinus SPII Hip Stem Target Trial Emulation (LARGE)
Launched by JOINTRESEARCH · Apr 10, 2024
Trial Information
Current as of July 26, 2025
Enrolling by invitation
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Listed in registry for primary hip arthroplasty.
- • Listed in registry with an indication of osteoarthritis, osteonecrosis or hip fracture.
- • Received the Lubinus SPII hip stem, 130mm or 150mm, for their primary hip arthro- plasty.
- • End point listed in registry (Alive, Deceased or revision).
- Exclusion Criteria:
- • Patients who received the Lubinus SPII 150 XL conus stem.
About Jointresearch
JointResearch is a leading clinical trial sponsor dedicated to advancing medical science through innovative research and collaboration. With a strong focus on developing novel therapies and improving patient outcomes, JointResearch partners with a diverse network of healthcare professionals, academic institutions, and industry leaders. The organization employs rigorous methodologies and state-of-the-art technology to ensure the integrity and reliability of its clinical studies. Committed to ethical standards and regulatory compliance, JointResearch aims to contribute significantly to the advancement of healthcare and the betterment of patient lives worldwide.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Amsterdam, Noord Holland, Netherlands
Patients applied
Trial Officials
Rudolf Poolman, Prof. Dr.
Study Chair
OLVG
Ariena Rasker, MSc
Principal Investigator
Joint research OLVG
Tijs de Koningh
Principal Investigator
Joint research OLVG
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported